PHARMAC publishes agenda for May 2024 PTAC meeting

PHARMAC

28 March 2024 - Another slim agenda; one cancer medicine.

The PTAC will consider funding applications for the following medicines at its next meeting on 16-17 May 2024:

  • Deflazacort - Duchenne muscular dystrophy
  • Selexipag - Pulmonary arterial hypertension
  • Macitentan - Pulmonary arterial hypertension
  • Pembrolizumab - Cervical cancer
  • Pembrolizumab - Renal cell carcinoma

Read PTAC agenda

Michael Wonder

Posted by:

Michael Wonder